Skip to main content

Packaging, labelling and marketing of pharmaceuticals has evolved rapidly in India, with concerns about ‘deceptive similarity’ at the helm. Our Pharma Dossier (Vol. 1) discusses trade mark jurisprudence in light of the primary factor – the consumer.

Whereas differentiation on the basis of a name may have become more constrictive, creative use of unconventional marks and branding exercises by pharmaceutical companies has aided the creation of unique identities. Useful, with the rate e-pharmacies are disrupting traditional distribution models.

 

To read more, contact us at email@anandandanand.com

Most Recent

News & Insights

VIEW ALL
News & Updates, Thought Leadership
Aug 30, 2026

I. The Infringer’s Privacy Paradox The Digital Personal Data Protection Act, 2023 (“DPDP Act”) is built around a clear rule. Personal data

The DPDP Act’s Unanswered Question: Can Privacy Law Block a Software Piracy Investigation?
News & Updates, Thought Leadership
Aug 05, 2026

‘First published on Asia IP’ By: Safir Anand and Ritu Bhargava India has taken important steps forward in protecting consumers who use its digital

Misleading ads and dark patterns: Evolving jurisprudence in India
News & Updates, Thought Leadership
Aug 01, 2026

On 24 May 2024, after roughly a quarter-century of negotiation, the Member States of the World Intellectual Property Organisation adopted, by consensus

WIPO GRATK Treaty: India Helped Write and Would Not Sign
News & Updates, Thought Leadership
Jul 18, 2026

‘First published on India Business Law Journal’ By: Madhu Rewari Artificial intelligence (AI) has changed the internet in both useful and unsettling

Preventing AI-powered domain name abuse